SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing extreme volatility and intense community frustration as the stock hits new lows, with investors debating whether the current sell-off is a structural collapse or a significant long-term buying opportunity. While some users point to concerns over content quality and management's failure to deploy buybacks, others are actively accumulating shares, viewing the stock as an oversold quality play ripe for a reversal.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing heightened volatility and selling pressure as investors weigh strong underlying fundamentals against broader software sector rotation and concerns over international contract developments. Community sentiment remains deeply polarized, with many retail participants actively debating whether to accumulate during the current price consolidation or exercise caution amid persistent short-selling activity.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors weigh its deep-pocketed infrastructure spending on AI data centers against its significant, long-term strategic stakes in high-growth companies like SpaceX. While the community is actively debating the company's capital allocation and the impact of recent talent turnover, many are focusing on the stock's potential as a core defensive play within the volatile hyperscaler sector.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing a surge in community engagement following the launch of their Americas Quantum Space Initiative, which has sparked speculation about potential partnerships and long-term space-based revenue growth. Investors are actively debating the stock's valuation versus peer quantum companies, with many looking toward an upcoming webinar on neutral-atom computing advancements as a potential catalyst for price movement.

Alphabet Inc - Ordinary Shares - Class C

Alphabet shares are seeing volatility driven by high-profile AI talent departures and market skepticism regarding the massive capital expenditures required to sustain the current AI buildout. Investors are actively debating the long-term sustainability of hyperscaler spending, while simultaneously weighing Alphabet's diversified growth engines like Google Cloud and the potential for lucrative future stake realizations.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon Athletica is facing heavy selling pressure and intense community debate as the stock hits multi-year lows, driven by concerns over declining margins, tariff impacts, and recent controversies in China. While some investors view the current valuation as a compelling long-term buying opportunity given the company's cash position and history of profitability, others are actively betting against the brand, citing failed leadership, weakening consumer demand, and the risk of further downward price action.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is facing significant volatility as community sentiment splits between investors focused on the company's long-term pivot toward AI data center infrastructure and those frustrated by its persistent correlation with Bitcoin's price fluctuations. Many traders are actively discussing the stock's recent technical rejections at key price levels, while simultaneously debating the impact of management's leadership and the potential for a short-term squeeze amidst heavy options activity.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors aggressively position for the highly anticipated release of 52-week Phase 3 VELA trial data, which is widely expected to validate sonelokimab's best-in-class potential in treating hidradenitis suppurativa. The community is actively debating the timing of this readout alongside other catalysts like the IZAR-1 trial for psoriatic arthritis, with sentiment heavily focused on the drug's superior nanobody structure as a prime target for a strategic acquisition by big pharma.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor activity and volatility as the community focuses on upcoming clinical trial catalysts, including the initiation of their phase 3 lung cancer program and anticipation of a major buyout opportunity. Investors are closely monitoring institutional accumulation and potential short-covering as they interpret recent tape movements and manufacturing progress as indicators of imminent, value-driving news.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing significant momentum driven by positive Phase 3 clinical trial data and increased investor optimism surrounding regulatory shifts for psychedelic therapies. The community is actively debating the potential for long-term valuation growth versus the risks of dilution and profit-taking after the stock's recent surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of "Hold" from Analysts

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) has been given a consensus rating of "Hold" by the eight ratings firms that are presently covering the company, Marketbeat...

MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc (Mereo BioPharma or the Company) (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS...

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud...

MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100Kto Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ...

MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026

MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi...

DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026 DEADLINE APPROACHING: Berger Montague...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action...

Shareholders that lost money on Mereo BioPharma Group plc(MREO) should contact Levi & Korsinsky about pending Class Action - MREO

Shareholders that lost money on Mereo BioPharma Group plc(MREO) should contact Levi & Korsinsky about pending Class Action - MREO Shareholders that lost money on Mereo BioPharma Group plc(MREO...

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit MREO Deadline: MREO Investors with Losses in Excess of $100K...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

Why Did RARE Stock Plunge Over 41% Today?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.3207
Prev Close	$0.3094
Open	$0.3166
Dividend Yield	0.00%
50-Day Moving Average	$0.2956
Beta	1.59
Avg. Volume	6.14M
PE Ratio	-1.38

52-Week High	$3.05
52-Week Low	$0.20
Market Capitalization	$49.39M
EPS (Annual)	-$0.2633
Price to Book	1.45
Revenue Per Employee	$12,850.46

MREOMereo Biopharma

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MREO News